Actionable news
0
All posts from Actionable news
Actionable news in REGN: Regeneron Pharmaceuticals, Inc.,

Regeneron Pharmaceuticals releases salary data. CEO sees compensation rise 13%

Regeneron Pharmaceuticals just filed its annual proxy statement, which details the salary information of its key executives. In 2015, the company's CEO made 47,462,526.

The table is included below:

Name and principal position
(a)







Year
(b)







Salary ($)
(c)







Bonus ($) 1
(d)








Stock
awards ($) 2
(e)











Option
awards ($) 2
(f)










All other
compensation ($) 3
(i)








Total ($)
(j)

Leonard S. Schleifer, M.D., Ph.D. 2015 1,200,000 2,880,000 43,307,918 4 74,608 5 47,462,526

President and Chief 2014 1,071,200 2,142,400 38,644,700 6 107,124 41,965,424

Executive Officer 2013 1,035,000 2,070,000 33,062,325 7 105,340 36,272,665
George D. Yancopoulos, M.D., Ph.D. 2015 1,020,000 2,448,000 36,811,837 4 22,519 8 40,302,356

President, Regeneron Laboratories 2014 910,500 1,821,040 32,744,746 6 30,525 35,506,811

and Chief Scientific Officer 2013 879,800 1,759,500 28,096,838 7 281,455 31,017,593
Robert E. Landry 2015 517,500 465,750 7,246,284 4 19,360 9 8,248,894

Senior Vice President, Finance 2014 500,000 455,000 10 6,403,138 6 14,818 7,372,956

and Chief Financial Officer* 2013 144,231 11 50,000 12 1,363,500 13 11,054,274 7 1,130 12,613,135
Neil Stahl, Ph.D. 2015 550,000 594,000 17,209,995 4 20,515 14 18,374,510

Executive Vice President, 2014 493,500 532,980 15,207,420 6 20,215 16,254,115

Research & Development 2013 476,800 386,208 13,474,403 7 17,235 14,354,646
Robert J. Terifay 2015 532,100 574,668 10,029,459 4 20,515 14 11,156,742

Executive Vice President, 2014 465,800 377,298 7,533,104 6 20,125 8,396,327

Commercial 2013 450,000 364,500 6,847,486 7 17,145 7,679,131

The above information was disclosed in a filing to the SEC. To see the filing, click here.

To receive a free e-mail notification whenever Regeneron Pharmaceuticals makes a similar move, sign up!

Other recent filings from the company include the following:

Regeneron: Form, Schedule Or Registration Statement No Filing Party: Date Filed: RELENTLESS INVENTION M E N U > C O N T E N T S 3 R E G E N E R O N AT A G L A NC E 4 S H A R EH O L D ER L E T T E - April 26, 2016
Regeneron Pharmaceuticals director just disposed of 1,000 shares - April 7, 2016
Regeneron Pharmaceuticals director just cashed-in 2,000 options - April 4, 2016